Stockhead

Special Report: The new Forteris treatment offers a material benefit compared to existing products in the market.

Animal health company Apiam (ASX:AHX) has again leveraged its global partnership network to provide a market-leading new product for its local client base.

AHX this morning confirmed the release of Forceris, a single-shot treatment that prevents iron deficiencies and controls the incidence of coccidiosis (an intestinal disease) in newborn piglets.

Read the full article below

MEDIA RELEASE

9 November 2020.
Bendigo Vic. Australia

Bringing Australian piglets to a higher level

Apiam confirmed today that a partnership with Ceva Animal Health Australia will deliver Australian pig farmers a new labour-saving technology solution to enhance piglet survival.

Forceris^TM, is Australia’s first single-shot combination of gleptoferron and toltrazuril, which prevents iron deficiency anaemia and controls coccidiosis in newborn piglets.

This patented technology will be available to Apiam clients from November, with enhanced supply enabling all Australia pig farmers access to this innovative solution in the following months.

One of the most common deficiencies in neonatal pigs is low iron levels. In combination with toltrazuril, Forceris contains Gleptoferron, a high-performance injectable iron demonstrated in trials as superior to common iron supplements currently on the market. Toltrazuril, is currently administered to piglets by oral application to treat coccidiosis which typically occurs in piggeries from 8 to 14 days of age.

It is estimated that over 5 million pigs in Australia are currently administered iron as part of routine best practice husbandry practices in the first 24-48 hours of life, with over 70% also administered a coccidiostat two to three days later. This single injection provides a single process event, reducing the handling costs and disruption to baby pigs in their critical first few days of life.

Apiam’s global relationships will once again benefit the Australian farmer. No double handling pigs increases efficiency at the farm level. The leading-edge iron supply, via the Gleptoferron molecule, provides optimal uptake and efficiency within the growing piglet. The high-quality single shot delivery system minimises wastage and allows precise delivery. “This is good for piglets and easy for farmers” said Dr Chris Richards, Managing Director for Apiam. These two points alone optimise growth, reduce labour requirements and assist animal welfare through less handling in the early days of life – a single action for a healthy start. In the past a two-pass process and an old technology iron molecule and potential for wastage of the coccidiostat which was administered by oral administration has meant underutilised potential for growers. “In one single injection, Forceris prevents iron deficiency anaemia and controls coccidiosis” Dr Richards said.

Apiam’s mission is to provide solutions that bring benefit to customers, not only at the individual animal level, but encompassing their whole production system. By partnering with Ceva to bring Forceris to the Australian market, Apiam’s vertically integrated veterinary business and strength in the Australian market were critical determining factors for Ceva to identify Apiam as its preferred partner to bring this innovation in the form of Forceris to the Australian market.

END

Contact

For media enquiries contact Chris Richards, Managing Director, Apiam Animal Health.

Email: chris@apiam.com.au

Fur Life Vet Kyabram Clinic and the Apiam Fur Life Foundation recognise and support the wonderful work our local wildlife carers provide for our beautiful and often endangered native animals.

We were very pleased to be able to support The Bohollow Wildlife Shelter with a donation of $10,000 allowing this dedicated service to continue its 24-hour rescue service throughout the Goulburn Valley.

Watch the Win News video featuring the Big Cheque Presentation here!

Weekly Times – Agribusiness 28 October 2020

Global sharemarkets are approaching record levels. See which listed agribusinesses have performed well.

AUSTRALIAN listed agribusiness companies have experienced mixed fortunes seven months after sharemarkets around the world crashed on March 23.

An analysis of share prices for a number of agribusiness has seen some of the previous top performers stumble, while those that have risen in price have varied from steady increases to 9-10 times crash levels.

It comes as global sharemarket indices have largely returned to pre-coronavirus levels, with some well above previous records.

The Australian Securities Exchange’s All Ordinaries Index ended last week at 6374 points, or 39.7 per cent higher than the 4564 points it plummeted to when the sharemarket crashed on March 23.

It has now exceeded its level the day prior to the crash and was now at 88 per cent of its record level of 7255 points in February this year.

The Australian share market has recovered better than Hong Kong’s Hang Seng index and the UK’s FTSE 100 Index, but was well behind Japan and the US sharemarkets.

The US technology index NASDAQ is about 17 per cent higher than its pre-coronavirus record set on February 19 this year and the S & P 500 Index, an index of trading in 500 top companies on a number of stock exchanges in the US, has also set a new record.

The largest agribusiness on the Australian Securities Exchange — The a2 Milk Company — ended last week at $14.45 a share, or 6.5 per cent lower than its $15.44 price on March 23.

The second largest agribusiness by market capitalisation, Treasury Wine Estates, has also fallen in value to levels lower than when global sharemarkets crashed.  

It ended last week at a price of $8.98, well below its March 23 level of $9.25.

Of the companies with a market capitalisation higher than $1 billion, Elders has performed the best.

Its share price ended last week at $11.45, or 56 per cent higher than its level of $7.33 on March 23.

Elders managing director Mark Allison said the company’s strong performance has been driven by diversification under successive eight-point plans.

Mr Allison said Elders’ growth between the first eight-point plan and the second eight-point plan just being completed came half from organic growth, with the other 50 per cent from acquisitions, such as Australian Independent Rural Retailers.

“We have a return on capital model with an emphasis on (containing) costs and capital management, so that in bad seasons, we make good money and in good seasons, we make great money,” he said.

At $3.58, horticultural producer Costa Group Holdings’ share price was now 46 per cent higher than its crash level of $2.51.

Among the smaller sized agribusinesses, veterinary service provider Apiam Animal Health has performed well, with its share price about 80 per cent higher than its level of 41 cents when the market crashed.

Apiam Animal Health chief executive officer Chris Richards said COVID-19 had contributed to the group’s fortunes, with more people buying pets during the pandemic to keep them company.

“The level of pet ownership increased significantly with people in lockdown,” Dr Richards said.

“Plus there were increased visits to vets, which coincided with our Best Mates program, a subscription model for pet care.

“On the farming side, our ProDairy program has also delivered growth in the dairy sector, also on the back of the excellent rainfall since January.”

Other strong performers on the ASX were regenerative agriculture company Wide Open Agriculture, whose share price was now nine times its March 23 level, and soil and animal health biotech company, Terragen, which was now trading at a multiple of five times its market crash level.

Stockhead Health & Biotech update

Special Report: The company’s strategic acquisition of ACE Laboratories is paying dividends as farmers seek alternatives to antibiotic health treatments.

Shares in animal health company Apiam (ASX:AHX) have almost doubled since March, amid a surge in pet ownership following the COVID-19 pandemic.

Apiam in the News

Animal health company Apiam (ASX:AHX) had some good news for the market yesterday, announcing a strong start to the 2021 financial year.

Apiam in the News

The Motley Fool: Apiam (ASX:AHX) share price soars 12% on strong Q1 update

Read the full article on The Motely Fool website via the link below!

Investor Newsletter October 2020

Apiam in the News

StockTalk: Animal health is a $67bn hidden gem

Apiam in the News

For animal health company Apiam Animal Health (ASX:AHX), the 2021 financial year marks an exciting opportunity for growth as it looks to capitalise on a multi-year consolidation strategy.